What we do—

Changing the world

UCLB is the commercialisation company of UCL and its partner NHS Trusts. We bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives.

Read More
Latest news—

BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

Valoctocogene Roxaparvovec Demonstrated Sustained Normal or Near Normal Factor VIII Levels in Severe Hemophilia A for Most Patients at Both Doses in Phase 1/2 Study.

Read More
Featured Technology—

Novel method of analysis of stroke data

Stroke is the leading cause of adult disability in the UK at an estimated cost of £7 billion a year. UCL has developed a system for predicting clinical outcomes so as to provide advance information on the optimum clinical management of each patient.
Read more
Spotlight—

Children are not small adults.

When it comes to the use of medicines, children cannot be treated as small adults.  Find out how our spinout, Therakind, is ensuring that children’s medicine used today is both safe and effective.

Read More
Featured Technology—

SnakeGrid

SnakeGrid is a way of developing low-distortion coordinate systems for large engineering projects.

Read more

Latest news and highlights

Read More News

BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

/ UCLB News
Valoctocogene Roxaparvovec Demonstrated Sustained Normal or Near Normal Factor VIII Levels in Severe Hemophilia A for Most Patients at Both ...

UCL spinout company Puridify Limited has been acquired by GE Healthcare

/ Spinout News, UCLB News
UCL spinout company, Puridify Limited, developers of bioprocessing technologies to significantly advance industrial biomolecule manufacture has been acquired by GE ...

BioMarin’s valoctocogene roxaparvovec a Breakthrough Therapy for hemophilia A

/ UCLB News
BioMarin today announced that the U.S. Food and Drug Administration (FDA) granted valoctocogene roxaparvovec (formally BMN 270) a Breakthrough Therapy ...

New licensing agreement for UCL technology to combat antimicrobial resistance

/ UCLB News
The alarming rise and spread of antimicrobial resistance is an increasing global challenge and there is considerable interest and an ...

FIND THE RIGHT MATCH

Whether you’re an academic or looking for technologies, find your UCLB contact here.

 

Bringing innovation to life

0
Active spinouts
0
Active licences in 2016
0
Drug discoveries
0
New patent applications